Small molecule glucagon release inhibitors with activity in human islets

PURPOSE: Type 1 diabetes (T1D) accounts for an estimated 5% of all diabetes in the United States, afflicting over 1.25 million individuals. Maintaining long-term blood glucose control is the major goal for individuals with T1D. In T1D, insulin-secreting pancreatic islet β-cells are destroyed by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalwat, Michael A., Rodrigues-dos-Santos, Karina, Binns, Derk D., Wei, Shuguang, Zhou, Anwu, Evans, Matthew R., Posner, Bruce A., Roth, Michael G., Cobb, Melanie H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157210/
https://www.ncbi.nlm.nih.gov/pubmed/37152965
http://dx.doi.org/10.3389/fendo.2023.1114799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157210/
https://www.ncbi.nlm.nih.gov/pubmed/37152965
http://dx.doi.org/10.3389/fendo.2023.1114799

Ejemplares similares